An Afghan man pleaded guilty to two terrorism-related offenses on Friday for plotting to carry out an Election Day attack. Nasir Ahmad Tawhedi, 27, told investigators he and co-conspirator ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.